Once-daily emtricitabine ['Coviracil'] is effective and well tolerated in patients with HIV infection, say researchers from Triangle Pharmaceuticals. Data were recently presented from studies FTC-302 and FTC-303, which compared triple therapy regimens containing once-daily emtricitabine or twice-daily lamivudine, and from a French study which evaluated the effectiveness of a once-daily regimen of emtricitabine, didanosine and efavirenz. The studies were presented at the 8th Conference on Retroviruses and Opportunistic Infections [Chicago, US; February 2001].